Identification of FXYD6 as the novel biomarker for glioma based on differential expression and DNA methylation

Abstract

AbstractObjectiveAs a single‐transmembrane protein of the FXYD family, FXYD6 plays different roles under physiological and pathological status, especially in the nervous system. This study aims to identify FXYD6 as a biomarker for glioma, by analyzing its expression and methylation patterns.MethodsUsing TCGA and GTEx datasets, we analyzed FXYD6 expression in various tissues, confirming its levels in normal brain and different glioma grades via immunoblotting and immunostaining. FXYD6 biological functions were explored through enrichment analysis, and tumor immune infiltration was assessed using ESTIMATE and TIMER algorithms. Pearson correlation analysis probed FXYD6 associations with biological function‐related genes. A glioma detection model was developed using FXYD6 methylation data from TCGA and GEO. Consistently, a FXYD6 methylation‐based prognostic model was constructed for glioma via LASSO Cox regression.ResultsFXYD6 was observed to be downregulated in GBM and implicated in a range of cellular functions, including synapse formation, cell junctions, immune checkpoint, ferroptosis, EMT, and pyroptosis. Hypermethylation of specific FXYD6 CpG sites in gliomas was identified, which could be used to build a diagnostic model. Additionally, FXYD6 methylation‐based prognostic model could serve as an independent factor as well.ConclusionsFXYD6 is a promising biomarker for the diagnosis and prognosis of glioma, with its methylation‐based prognostic model serving as an independent factor. This highlights its potential in clinical application for glioma management.